

North Central Cancer Treatment Group

N0776: Phase II Trial of Avastin® in Combination with Sorafenib in Recurrent Glioblastoma Multiforme

Addendum 17 – November 25, 2011

Summary

- Due to the high quality of work performed by HistoGeneX in Belgium, a select number of IHC assessments will now be done by HistoGeneX rather than the TACMA laboratory at the Mayo Clinic Rochester. Therefore, the Pathology Considerations/Tissue Biospecimens section has been revised accordingly.
- Administrative changes.

A replacement protocol is provided. Please replace the current copy with the one attached. Please keep this addendum with your protocol

Title page Updated to reflect the addition of Addendum 17 and revised NCI version date.

Protocol Resources

Page 2: **Sanna L. McKinzie** replaces ~~John (Jack) M. Beranek~~ as the NCCTG Research Base Research Protocol Specialist.

Section 17.0 Pathology Considerations/Tissue Biospecimens

Page 64: A select number of IHC assessments will now be done by HistoGeneX. Therefore, Section 17.5 has been revised as follows:

17.51 Immunohistochemistry (IHC) on tumor samples obtained at baseline will have the following antigens analyzed in the TACMA Shared Resource at Mayo Clinic Rochester:

- ~~CD31~~
- VEGFR1
- VEGFR2
- VEGFR3
- PDGFR α
- PDGFR β
- ~~VEGF~~
- CA-9
- HIF1 α
- HIF2 α
- ~~NRP-1~~
- NRP-2
- Phospho-ERK

17.52 The following additional IHC assessments will be performed on baseline tumor samples by HistoGeneX (Antwerp, Belgium):

- CD31
- VEGFR1
- VEGFR2
- VEGFA
- NRP-1

HistoGeneX offers IHC services in a quality-driven environment. All assays are optimized, implemented and validated according to strict quality assurance standards that are based on CAP, BELAC, and CLIA guidelines. At present, HistoGeneX provides over 80 assays covering the fields of oncology and neuropathology. Five 5-micron unstained charged slides and one H&E slide will be shipped to the following address for assaying and analysis:

**HistoGeneX
Sofie Vande Velde
Campus Middelheim-Pathology
Linderdreef 1
B-2020 Antwerp
Belgium**

Pages 64-65: Due to the newly added Section 17.52, all remaining sections have been renumbered.

Pages 64-68: Repagination has occurred.